Skip to main content
Deutsch

Detail

  1. Home
  2. Research
  3. Researcher Profiles
  4. Researcher Profiles
  5. Detail
Gerd Jomrich
Priv. Doz. Dr.med.univ. Dr. scient.med. Gerd Jomrich

Department of General Surgery (Division of Visceral Surgery)
Position: Consultant

ORCID: 0000-0002-7294-4831
T +43 1 40400 56210
gerd.jomrich@meduniwien.ac.at

Further Information

Keywords

Barrett Esophagus; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fibroblast Growth Factors; Gastrectomy; Gastroesophageal Reflux; Inflammation; Neoadjuvant Therapy; Pancreatic Cancer; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pancreatitis; Receptors, Fibroblast Growth Factor; Translational Medical Research

Research group(s)

Research interests

  • Local and Systemic Inflammation in Gastric, Esophageal and Pancreatic Cancer
  • Molecular Peritoneal Staging in Gastric, Esophageal and Pancreatic Cancer
  • Expression of Fibroblast Growth Factors and its Receptors in (neoadjuvantly treated) Gastric, Esophageal and Pancreatic Cancer
  • Prognostic Value of Preoperative Laboratory Results in Gastric, Esophageal and Pancreatic Cancer
  • Biobanking: Establishing a Biobank for Upper-GI and Pancreatic Malignancies
  • Perioperative Stress-Induced Biomarkers on Stress Signaling Receptors in Esophageal and Pancreatic Cancer Patients

Techniques, methods & infrastructure

  • Upper-GI Biobank
  • Pancreatic Cancer Biobank
  • Analyzing Esophageal and Pancreatic Cancer RNASeq Data from TCGA (The Cancer Genome Atlas)
  • Immunohistochemistry (IHC)
  • Quantitative RT-PCR
  • Retrospective Clinical Studies

Selected publications

  1. Jormich G. et al., 2022. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. Available at: https://pubmed.ncbi.nlm.nih.gov/34404561.
  2. Jomrich, G. et al., 2021. High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma. Available at: https://pubmed.ncbi.nlm.nih.gov/31425286/.
  3. Jomrich, G. et al., 2019. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.Available at: https://www.mdpi.com/2073-4409/8/9/1092.
  4. Jomrich, G. et al. (2019) ‘Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection’, Journal of Gastrointestinal Surgery, 24(3), pp. 610–618. Available at: http://dx.doi.org/10.1007/s11605-019-04187-z.
  5. Jomrich, G. et al. (2019) ‘High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma’, Annals of Surgical Oncology, 26(4), pp. 976–985. Available at: http://dx.doi.org/10.1245/s10434-019-07186-1.